Levetiracetam
Product Images NDC 50090-2815

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-2815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (7316b619 C812 4279 8c99 1105f0ff3508 01)

Chemical structure of Levetiracetam showing its molecular arrangement including a pyrrolidone ring, an ethyl group, and an amide group linked to a central carbon atom.*

FDA Label Image

Fig 1 (7316b619 C812 4279 8c99 1105f0ff3508 02)

A bar chart comparing the percentage of patients among three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients from 0% to 45%, with the bars showing approximately 7.4% for Placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day. Sample sizes are noted under each group label.*

FDA Label Image

Fig 2 (7316b619 C812 4279 8c99 1105f0ff3508 03)

A bar chart showing the percentage of patients in three groups: Placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%, N=105). The y-axis represents the percentage of patients from 0% to 45%, and each bar is labeled with respective values and sample sizes.*

FDA Label Image

Fig 3 (7316b619 C812 4279 8c99 1105f0ff3508 04)

A bar graph comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients, ranging from 0% to 45%. An asterisk is shown above the Levetiracetam bar, indicating statistical significance.*

FDA Label Image

Fig 4 (7316b619 C812 4279 8c99 1105f0ff3508 05)

A bar chart comparing the percentage of patients responding to Placebo and Levetiracetam treatments. The chart shows 19.6% for Placebo (N=97) and 44.6% for Levetiracetam (N=101), with an asterisk indicating statistical significance for the Levetiracetam group. The y-axis is labeled as % of Patients.*

FDA Label Image

5 (7316b619 C812 4279 8c99 1105f0ff3508 06)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The Placebo group shows 19.6% of patients, while the Levetiracetam group shows 43.1% of patients. The chart includes a vertical axis labeled '% of Patients' ranging from 0% to 45%.*

FDA Label Image

Fig 6 (7316b619 C812 4279 8c99 1105f0ff3508 07)

A bar graph comparing the percentage of patients between placebo (N=84) and Levetiracetam (N=79) groups. The Levetiracetam group shows a higher percentage at 72.2% compared to 45.2% for the placebo group.*

FDA Label Image

Logo (7316b619 C812 4279 8c99 1105f0ff3508 08)

FDA Label Image

Logo (7316b619 C812 4279 8c99 1105f0ff3508 09)

FDA Label Image

Label Image (Lbl500902815)

Levetiracetam 500 mg tablet label from A-S Medication Solutions featuring the product number 9067-0. The label includes storage instructions to keep the product between 68 to 77 degrees Fahrenheit and specifies a quantity of 32 unit dose tablets. Additional details include distributor information and the product NDC 50090-2815-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.